Vascular Stent Market

The vascular stents market is projected to reach USD 15.6 billion by 2029 from USD 11.4 billion in 2024, at a CAGR of 6.5% during the forecast period. The growth of the vascular stents market is primarily attributed to the increasing incidence of vascular diseases (such as coronary artery diseases, peripheral artery diseases, and endovascular aortic aneurysms) and the rising uptake of angioplasty procedures. The growing preference for minimally invasive surgical procedures is also expected to contribute to market growth. However, the availability of open surgical procedures, such as open heart surgeries, and the increasing number of product recalls are expected to restrain the market growth to a certain extent. Additionally, the potential of emerging economies and the development of bioresorbable vascular scaffold stents are expected to provide growth opportunities for market players during the forecast period.

Attractive Opportunities in the Vascular Stents Market

To know about the assumptions considered for the study, Request for Free Sample Report

Market Dynamics

Driver: Growing preference for minimally invasive procedures

The market for vascular stents is primarily driven by the growing preference and demand for minimally invasive surgical procedures. Patients are increasingly opting for angioplasty and other-related procedures owing to several advantages, including shorter recovery periods, minimal post-surgery complications, and smaller incisions. Maintaining arterial blood flow is essential for treating peripheral artery disease (PAD) and coronary artery disease (CAD). Consequently, there is a growing need for advanced medical procedures such as stenting, a standard method used in angioplasty. Therefore, the increasing demand for vascular stents is driven by the subsequent rise in chronic heart conditions. For instance, in 2021, over a million percutaneous coronary interventions (PCIs) were performed annually in the US, and 1.1 million transluminal coronary angioplasties were performed across 25 EU nations. These statistics demonstrate the crucial role that stents play in delivering contemporary vascular therapy.

Restraint: Stringent regulatory guidelines for product approval

The growth of the vascular stents market is expected to be hindered by stringent regulatory policies and guidelines related to medical device approval. These regulations aim to ensure the efficacy & safety of vascular stents. Clinical efficacy must also be considered, in addition to meeting stringent quality standards. The mandatory compliance may lead to businesses bearing hefty financial & operational burdens that may impede the ability to develop & launch innovative stent technologies. Financial obstacles like protracted approval processes and high compliance fees can also limit patients' access to advanced stenting products.

Opportunity: Development of bioresorbable vascular scaffold stents 

Vascular stents offer a substantial growth opportunity in developing bioresorbable vascular scaffolds (BRS) stents. BRSs, as opposed to permanent metallic stents, offer transient mechanical support to the vascular wall before progressively dissolving to lessen the chance of adverse reactions and reduce the presence of foreign bodies in time. The growing popularity of bioresorbable materials is expected to contribute to market growth. Continuous advancements in medical devices are expected to increase the safety & efficacy of vascular stents in the coming years. The prominent firms offering bioresorbable stents for the treatment of cardiac & peripheral vascular diseases include BIOTRONIK SE & Co. KG (Germany), Arterius Ltd. (UK), and Meril Life Sciences Pvt. Ltd (India).

Challenge: Complications associated with stenting procedures

Issues with stents are a primary risk to clinical outcomes, procedural success rates, and patient safety throughout treatment. Allergy to chemicals or imaging dyes used during the treatment is a common side effect that can lead to unpleasant responses, extended hospital stays, and the increasing need for additional medical interventions. Hemorrhages at the operation location may hinder recovery, thus escalating medical expenses and resulting in lower patient satisfaction. Hence, healthcare professionals are hesitant to opt for stenting procedures, which may eventually alter market dynamics and hinder widespread adoption.

Ecosystem Market/Map

“By technology, the covered stents segment accounted for the largest market share in 2023”

Based on technology, the vascular stents market is segmented into drug-eluting stents, covered stents, bare metal stents, and bioabsorbable stents. In 2023, the covered stents segment accounted for the largest share of the market. Covered stents consist of a metal stent encased in fabric or graft material, such as polytetrafluoroethylene (PTFE). The growth of the covered stents segment is attributed to its creative design and improved therapeutic advantages. The issue of restenosis is decreased by the exceptional ability to exclude plaque and avoid in-stent neointimal hyperplasia. Additionally, these stents close artery ruptures and encourage ideal hemodynamic flow through a newly formed flow channel, reducing the risks of distal embolization, perforation, rupture, and dissection. 

“By product type, the femoral artery stent segment accounted for the largest market share in 2023”

Based on product type, the market is categorized into carotid artery stents, femoral artery stents, renal artery stents, iliac artery stents, and other peripheral stents. Of these, the femoral artery stents segment accounted for the largest share of the market in 2023. Healthcare professionals frequently perform femoral artery percutaneous transluminal angioplasty (PTA) to address atherosclerosis effectively. A stent implantation is necessary for this surgery to maintain arterial patency and regulate the blood flow. These stents are a crucial intervention for regulating vascular health.

“By end user, the hospitals segment accounted for the largest market share in 2023”

The vascular stents market is segmented into hospitals and cardiac centers. In 2023, the hospitals segment accounted for the largest share of 55.5% of the vascular stents market. The key factors driving the market growth of the hospitals segment include the rising establishment of hospitals worldwide and the increasing cases of hospitalization owing to angioplasty procedures. The growing incidence of cardiovascular diseases is expected to drive the demand for advanced treatment products like vascular stents. This expansion is further stimulated with the adoption of vascular stents for cardiac issues. For instance, according to the Minnesota Department of Health, the state received over 46,000 hospital admissions for heart disease in 2021, which is 668 hospital admissions per 100,000 residents. This number emphasizes the crucial role of hospitals in delivering stent-based therapies and enunciates the growth of this end-user segment during the forecast period.

“By region, North America accounted for the largest market share in 2023”

To know about the assumptions considered for the study, download the pdf brochure

Based on region, the vascular stents market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. In 2023, North America accounted for the largest market share due to the rising incidence of cardiovascular diseases, such as coronary artery disease, and the rising uptake of angioplasty procedures. According to the Centers for Disease Control and Prevention, heart disease accounted for 702,880 deaths in the US in 2022—which accounts for one out of every five deaths. This figure highlights the increasing demand for stents. Additional market growth factors include the rising healthcare expenditure, the high adoption of advanced technologies, and the presence of leading stent manufacturers in the region.

Key Market Players

The leading players in the vascular stents market are Medtronic Plc (Ireland), Abbott Laboratories (US), Boston Scientific Corporation (US), B Braun SE (Germany), Terumo Corporation (Japan), Biotronik SE & Co.KG (Germany), Shanghai Microport Medical (Group) Co., Ltd (China), Meril Life Science Pvt. Ltd (India), Sahajanand Medical Technologies Limited (India), Becton, Dickinson, and Company (US), W.L. Gore & Associates, Inc (US), Cordis Corporation (US), Artivion Inc (US), Stryker Corporation (US), LifeTech Scientific Corporation (China), Translumina (Germany), Lepu Medical Technology (Beijing) Co., Ltd (China), Endologix LLC. (US), Biosensors International Group, Ltd (Singapore), Cook Medical (US), Insitu Technologies Inc (US), iVascular (Spain), OrbusNeich Medical Group Holdings Limited (China), Alvimedica (Turkey), and Elixir Medical (US).

Want to explore hidden markets that can drive new revenue in Vascular Stent Market?

Unlock Insights

Click on image to enlarge

Scope of the Report

The study categorizes the Vascular stent Market based on technology, product, mode of delivery, material, end user at regional and global level.

Vascular stent market, by technology

• Drug-eluting stents
• Covered stents
• Bare-metal stents
• Bioabsorbable stents

Vascular stent market, by Product

• Coronary stents
• Peripheral stents
  • Carotid artery stents
  • Renal artery stents
  • Femoral artery stents
  • Iliac artery stents
  • Other peripheral stents
• EVAR Stent Grafts
  • Abdominal aortic aneurysm stent grafts
  • Thoracic aortic aneurysm stent grafts

Vascular stent market, by mode of delivery

• Ballon-expandable stents
• Self-expanding stents
• Vascular stent market, by material
• Metallic materials
  • Cobalt Chromium
  • Platinum chromium
  • Stainless steel
  • Nickel titanium
• Polymer materials
  • Biodegradable polymer
  • Non-biodegradable polymer

Vascular stent market, by End-User

• Hospitals
• Cardiac Centers

Vascular stent market, by region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • RoE
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South korea
  • RoAPAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • Rest of Middle East and Africa

Recent Developments:

• In May 2024, Abbott Laboratories launched the XIENCE Sierra Everolimus Drug-eluting Coronary Stent System in India. XIENCE Sierra is one of the latest generation stents in the XIENCE family, designed for individuals with blocked coronary arteries.
• In April 2024, Abbott Laboratories declared that the US FDA had approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), marking a breakthrough innovation for individuals with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK).
• In May 2022, Medtronic plc announced that it had received the US FDA approval for the Onyx Frontier drug-eluting stent (DES).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst